Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
LEO Pharma has recently completed the first phase of its strategic transformation process – including the development of a new capital and governance structure. During her more than two years as President and CEO, Catherine Mazzacco has successfully led this effort and developed the company’s sales and marketing capabilities while at the same time building a strong executive leadership team.
The next phase of LEO Pharma’s transformation is focused on preparing the company for an IPO within a four-to five-year time horizon. This requires a focus on operational efficiency, shareholder and capital markets engagement, and driving the internal strategic transformation of the organization.
The Board of Directors and Catherine Mazzacco have together concluded that this would be the right time for LEO Pharma to recruit a new CEO. Catherine Mazzacco is stepping down from her role and leaving the company on November 30, 2021.
Catherine Mazzacco says:
“It has been a privilege to be the CEO of LEO Pharma and I have a tremendous affection for LEO Pharma employees and their high level of engagement for the company. I am proud of the accomplishments we have achieved together in setting an ambitious strategy for the company, completing a comprehensive efficiency improvement program, establishing a new capital structure and advancing the launch of a major new therapy.”
The Chairman of the Board Jesper Brandgaard says:
“On behalf of the Board, I would like to express our sincere thanks to Catherine Mazzacco for her commendable efforts in leading the transformation of LEO Pharma towards a leadership position in the innovative space of medical dermatology. Catherine Mazzacco has been instrumental in driving the company’s ambitious growth strategy towards 2030.”
The Board of Directors has initiated a search process for the next CEO. Until a new permanent CEO is in place, the current LEO Pharma CFO, Anders Kronborg, will step in as acting CEO, and the Chairman of the Board, Jesper Brandgaard, will act as Executive Chair.
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10.133 billion.